Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06506916 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 16
- Study locations
NCT06506916: Recruiting Phase 3 study of Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL.
NCT06506916 is a Phase 3 study of Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 90 participants, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (89% lower). The trial reports 16 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06506916, a Phase 3 study of Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Primary Outcome
Composite gene expression score using RT-PCR in lesional skin at Baseline and Week 48 using preselected genes based on bimekizumab mechanism of action and PSO disease biology pathways.
Conditions Studied
Interventions
- DRUG bimekizumab
Study Locations (16)
Other
- Ps0039 40515 - Berlin
- Ps0039 40287 - Frankfurt am Main
- Ps0039 40072 - Freiburg im Breisgau
- Ps0039 40775 - Witten
- Ps0039 40347 - Lodz
- Ps0039 40757 - Poznan
- Ps0039 40625 - Warsaw
- Ps0039 40761 - Warsaw
- Ps0039 40773 - Wroclaw
California
- Ps0039 50162 - Fountain Valley
- Ps0039 50642 - Santa Monica
Alabama
- Ps0039 50140 - Birmingham
Florida
- Ps0039 50283 - Tampa
Michigan
- Ps0039 50110 - Ann Arbor
New York
- Ps0039 50643 - Rochester
Pennsylvania
- Ps0039 50491 - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2028-03-14 |
| Phase | Phase 3 |
What NCT06506916 shows while recruiting
NCT06506916 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which bimekizumab is the first listed.
NCT06506916 lists 16 locations in 7 states (Other, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT06506916 about?
NCT06506916 is a clinical study titled "A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biop...
What is the current status of trial NCT06506916?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2024-07-29. Estimated completion is 2028-03-14.
What conditions does trial NCT06506916 study?
This clinical trial studies the following conditions: Psoriatic Arthritis, Moderate to Severe Plaque Psoriasis.
What interventions are being tested in trial NCT06506916?
The interventions under investigation include: bimekizumab (DRUG).
Who is sponsoring clinical trial NCT06506916?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06506916 being conducted?
This trial has 16 study locations across Alabama, California, Florida, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06506916's enrollment target sits among peer trials
90 39th of 48 higher than 9 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI